The chemopreventative effects of dithiolethione compounds are attributed to their activation of antioxidant response elements (AREs) by reacting with the Nrf2/ Keap1 protein complex. In this study, we show antiproliferative effects of the dithiolethione compound ACS-1 in human cancer cell lines (A549 and MDA-MB-231) by increasing the activity of the tumor suppressor protein phoshatase 2A (PP2A). ACS-1 inhibited epidermal growth factor (EGF)-induced cellular proliferation in a concentration-and time-dependent manner. Akt activation, as determined by serine-473 phosphorylation, was inhibited by ACS-1 in cells stimulated with either EGF or fibronectin. Furthermore, ACS-1 inhibited mammalian target of rapamycin signaling and decreased c-myc protein levels. ACS-1 did not proximally alter EGF receptor or integrin signaling, but caused a concentration-dependent increase in PP2A activity. The effect of ACS-1 on Akt activation was not observed in the presence of the PP2A inhibitor okadaic acid. ACS-1 effects on PP2A activity were independent of ARE activation and cAMP formation. In addition to ACS-1, other dithiolethione compounds showed similar effects in reducing Akt activation, suggesting that this class of compounds may have other effects beyond chemoprevention.
Introduction
Dithiolethione-containing compounds have shown cytoprotective and chemopreventive properties in animal models as well as clinical trials (Zhang and Munday, 2008) . Although the clinical application of the dithiolethione oltipraz in smokers have revealed adverse side effects that discouraged the therapeutic use of this compound, (Zhang and Munday, 2008) anethole dithiolethione (ADT) has been administered safely without complications and is clinically used for xerostomia (Hamada et al., 1999) . Bronchial dysplasia is one of the best surrogate end point markers available for the assessment of novel chemopreventive drugs. The application of ADT in a phase IIb clinical study showed chemopreventive effects of ADT in smokers with bronchial dysplasia as characterized by statistically significant reductions in the appearance of new lesions, the progression rate of pre-existing lesions, as well as overall disease progression of the patient (Lam et al., 2002) . The chemopreventive and cytoprotective effects of dithiolethiones arise from their ability to activate the antioxidant response element (ARE) by direct interaction with the KEAP1/Nrf2 complex (Kwak et al., 2003; Lee and Surh, 2005) . Genes that are positively regulated by ARE include Phase II enzymes, such as heme oxygenase-1 (HO-1), glutathione S-transferase and NQO1, and the overall net effect is to defend the cell from oxidative or xenobiotic stress (Kwak et al., 2001) .
The PI3K/Akt signaling pathway is a major contributor to cellular proliferation, and mutations in this pathway are common in human cancers (Yuan and Cantley, 2008) . PI3K is activated by a number of extracellular stimuli and results in the formation of PIP3 that is required for Akt activation. Akt kinase activity has multiple effects in cancer progression, including an increase in tumor angiogenesis, cancer cell invasion and metastatic potential (Dillon et al., 2007; Qiao et al., 2008) . Akt activity is negatively regulated by protein phoshatase 2A (PP2A) (Andjelkovic et al., 1996; Resjoë t al., 2002) . PP2A is comprised of three families of subunits whose combined activity and cellular localization depends upon the exact subunit composition and selected post-translational modifications (Eichhorn et al., 2009) . PP2A is considered to have tumor suppressor activities that also function on other proteins involved in cancer progression such as RalA and c-myc (Sablina et al., 2007; Arnold and Sears, 2008) . In this report, we investigate the antiproliferative effects of dithiolethiones in aggressive human breast and lung cancer cell lines. ACS-1, a prototypical dithiolethione, inhibited Akt and mammalian target of rapamycin (mTOR) activation from both epidermal growth factor (EGF) or fibronectin (FN) stimulation and inhibited cell proliferation in a dose-dependent manner. We show here that ACS-1 increases the activity of the tumor suppressor PP2A and that the inhibition of proliferation is sensitive to PP2A inhibition. The antiproliferative effects were independent of ARE activation and suggests a novel mechanism for this class of compounds beyond interacting with KEAP1/Nrf2 complex. Therefore, these compounds may have utility in the treatment of human cancers by activating a known tumor suppressor as well as cancer prevention.
Results
Our previous work has suggested that the ACS-1 component, a dithiolethione with a similar structure to ADT (Figure 1 ), of S-NSAIDs causes a decrease in cancer cell proliferation (Moody et al., 2009) . EGF has been shown to mediate cancer cell proliferation by activating the PI3K/Akt/mTOR pathway, which may provide therapeutic targets (Dillon et al., 2007; Carnero et al., 2008) . Toward this end, we tested the potential therapeutic effect of ACS-1 on EGF-induced cell proliferation. Adherent A549 or MDA-MB-231 (MB231) cells were grown in serum-free media supplemented with EGF þ /ÀACS-1 and cells were counted at the indicated times. ACS-1 inhibited both A549 (Figure 2a ) and MB231 ( Figure 2b ) proliferation in a concentration-dependent manner. In addition, ACS-1 inhibited cell proliferation in A549 ( Figure 2c ) and MB231 (data not shown) cells, grown in media containing 10% fetal bovine serum (FBS), compared with untreated controls. Cell cycle analysis of MB231 cells show that ACS-1 caused a G 0 / G 1 block and inhibited progression into S phase as compared with serum controls (Figure 2d and Table 1) , while showing no indication of dead or dying cells.
As ACS-1 inhibited cellular proliferation in response to EGF stimulation, the effect of ACS-1 on epidermal growth factor receptor (EGFR) signaling was examined. Serum-starved MB231 cells were treated with ACS-1 for 2 h at 37 1C followed by EGF stimulation for 2 min. ACS-1 did not affect EGFR activation as represented by tyrosine-992 phosphorylation when normalized to total EGFR (Figure 3a ). EGFR phosphorylation mediates activation of the PI3K pathway and PIP3 formation. Although enhanced PIP3 levels mediate increases in pPDK1-(serine 241) as well as pAkt-(thr 308), complete activation of Akt is dependent upon phosphorylation at serine 473, which is mediated by mTOR/RICTOR (Hresko and Mueckler, 2005) . ACS-1 significantly suppressed EGF-mediated Akt-(ser 473) phosphorylation (Figures 3a and b) at concentrations of 50 mM and higher but had little to no effect on pPDK1-(serine 241) ( Figure 3a ) or pAkt-(thr 308) (data not shown). Similar results were observed in the A549 cell line (Figure 3c ). At concentrations consistent with the inhibition of Akt-(ser 273) phosphorylation, ACS-1 also inhibited EGFinduced mTOR activation in MB231 cells (Figure 3e ), a downstream substrate of active Akt.
Mechanisms other than growth factor receptor activation mediate Akt signaling in human cancers. Extracellular matrix proteins (for example, FN, laminin) activate extracellular integrin complexes to initiate intracellular signaling by integrin-linked kinase (ILK) activity, which directly activates Akt (Danen and Yamada, 2001; Persad and Dedhar, 2003) . To address the effects of ACS-1 on Akt stimulation by integrin activation, A549 cells were plated on increasing concentrations of FN. Figure 4a shows an FN-dependent increase in pAkt-(ser 473), which is concentration dependently suppressed by ACS-1 ( Figure 4b ). Moreover, ACS-1 also suppressed FN-mediated mTOR (ser 2448) activation ( Figure 4b ). ACS-1 had no effect on integrin signaling at the level of ILK activity (Figure 4c ), which phosphorylates Akt ser473. ILK activity was unchanged with respect to ACS-1 concentration as determined by phosphorylation of recombinant Akt, suggesting that ACS-1 targets are downstream of ILK.
As ACS-1 suppressed Akt phosphorylation without proximally affecting EGFR or integrin signaling, we surmized that ACS-1 might impact a downstream target specific to Akt regulation. A major endogenous negative regulator of Akt signaling is PP2A (Andjelkovic et al., 1996; Sato et al., 2000; Resjo¨et al., 2002; Ugi et al., 2004; Rocher et al., 2007) . To examine a potential role of ACS-1 in targeting PP2A, serum-starved A549 or MB231 cells were treated with ACS-1 and okadaic acid (50 nM), an inhibitor of PP2A, for 2 h and then stimulated with EGF. Figures 5a and b show inhibitory effects of okadaic acid on ACS-1-mediated suppression of pAkt-(ser 473) in EGF-stimulated cells, indicating that PP2A may be a critical target of the antiproliferative properties of ACS-1.
The proto-oncogene c-myc is an endogenous substrate for PP2A and dephosphorylation of c-myc by PP2A promotes the ubiquitination and subsequent proteasomal degradation of c-myc Sears, 2006, 2008) . A549 and MB231 cells were incubated with ACS-1 for 2 h and then stimulated with EGF for 30 min. ACS-1 caused a concentration-dependent decrease in total c-myc protein levels in MB231 cells (Figure 5c ) that is not observed in the presence of okadaic acid. To directly measure cellular PP2A activity, the PP2A catalytic subunit was immunoprecipitated from whole cell lysates and assayed for phosphatase activity using a PP2A-specific synthetic phospho-peptide substrate. PP2A activity was significantly decreased in cells treated with EGF compared with untreated cells. However, the ACS-1 pretreatment of EGF-stimulated cells caused a dose-dependent increase in PP2A activity in both MB231 ( Figure 5d ) and A549 cells (data not shown). 
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In both cell lines, pretreatment with 50 mM ACS-1 returned PP2A activity to near basal levels, whereas 100 mM ACS-1 caused a 1.5-fold increase in activity beyond basal levels. Moreover, the time of ACS-1 exposure is sufficiently short to preclude increased PP2A translation ( Figure 5e ). Taken together, these results suggest a role of ACS-1 in post-translationally targeting PP2A at the level of activity. Heme oxygenase-1, a gene product that is induced by dithiolethiones through Nrf2/ARE, is not induced within the exposure time of ACS-1 that elicited the increase in PP2A activity (Figure 6a ). In addition, the inhibition of pAkt-(ser473) by ACS-1 is not affected by the presence of the protein synthesis inhibitor G418 (data not shown). Furthermore, phase II genes are not fully activated by ACS-1 within the 2 h of PP2A activation, but are subsequently activated at later time points as determined by reverse transcription-PCR of MB231 cells treated with 50 mM ACS-1 ( Figure 6b ). Therefore, it appears that ACS-1 activates the tumor suppressor PP2A independent of de novo protein synthesis and PP2A functions to inhibit Akt signaling independently of Nrf2/ARE activation.
Protein phoshatase 2A activity is increased by forskolin by increasing intracellular cAMP levels (Feschenko et al., 2002) . To determine if ACS-1 induced PP2A activity by a similar mechanism, serum-starved MB231 cells were treated with a phosphodiesterase inhibitor, IBMX, and either forskolin or ACS-1 for 2 h and total intracellular cAMP levels were determined by enzyme-linked immunosorbent assay. Forskolin caused a significant increase in cAMP compared with untreated control, whereas ACS-1 caused a significant decrease in cAMP ( Figure 6c ). These results suggest that ACS-1 increases PP2A activity in a manner that is independent of cAMP.
Discussion
Dithiolethiones are known to exert cellular chemopreventive effects by activating the KEAP1/Nrf2/ARE pathway; however, the major findings of this report are that dithiolethiones interact with chemical motif targets other than the Keap1/Nrf2 complex and that interaction with one of these target chemical motifs results in the activation of the tumor suppressor PP2A. Dithiolethione activation of PP2A has antiproliferative effects in aggressive breast and lung cancer cell lines, as PP2A acts as a negative regulator of Akt and mTOR signaling. These results indicate that in addition to the chemopreventive properties, which have previously been shown, this class of compounds show antimitogenic effects that may also impact cancer progression and metastasis. ACS-1 caused a dose-and time-dependent decrease in cellular proliferation in both A549 and MB231 cell lines stimulated with either FBS or recombinant EGF. This observation is a novel function for the dithiolethione class of compounds, as previous reports have identified properties associated with chemoprevention and radioprotection (Kim et al., 1998; Kwak et al., 2001; Zhang and Munday, 2008) . Stimulation of A549 and MB231 cells with EGF or FN resulted in the activation of the PI3K/Akt/mTOR pathway, which is a dominant signaling pathway that controls cell proliferation in many cancers (Dillon et al., 2007; Carnero et al., 2008) . Multiple mutations in the PI3K/Akt/mTOR pathway as well as the overexpression of endogenous activators of this pathway are common in human tumors (Yuan and Cantley, 2008) . ACS-1 caused a dose-dependent inhibition of Akt (ser 473) phosphorylation in A549 and MB231 cell lines stimulated with either EGF or FN with an approximate IC 50 of 50 mM. Furthermore, ACS-1 inhibited the activation of mTOR, a downstream target of active Akt kinase with a similar IC 50 concentration. ACS-1 increases PP2A activity CH Switzer et al
As ACS-1 inhibited Akt signaling in both EGF-and integrin-stimulated cells, but did not cause a change in PDK1 phosphorylation, EGFR activation or ILK activity, we concluded that ACS-1 operates on a common downstream target (Figure 7) . A major negative regulator of Akt signaling is the ubiquitous protein phosphatase PP2A, a tumor suppressor, which functions to dephosphorylate and thus reduce Akt kinase activity (Andjelkovic et al., 1996; Resjo¨et al., 2002) . ACS-1 failed to inhibit Akt signaling in cells treated with the PP2A inhibitor okadaic acid, which suggests that PP2A or a related phosphatase activity is required for the inhibition of Akt signaling by ACS-1. Furthermore, PP2A immunoprecipitated from ACS-1treated cells verified that ACS-1 did indeed increase total PP2A activity when compared with untreated control. Moreover, EGF stimulation of cells caused a significant decrease in PP2A activity compared with unstimulated serum-starved cells, and is consistent with previous reports (Chen et al., 1992; Ugi et al., 2002) . However, EGF-stimulated cells treated with ACS-1 showed a dose-dependent increase in PP2A activity. PP2A activity returned to levels comparable with unstimulated serumstarved cells with 50 mM ACS-1 and exceeded basal levels at 100 mM. These results suggest that increased PP2A activity mediates Akt inhibition by ACS-1 in EGFstimulated cells. In addition to altering Akt signaling, c-myc is a substrate for PP2A phosphatase activity and negatively regulates c-myc protein levels by the induction of ubiquitin-dependent proteolysis Sears, 2006, 2008; Trotta et al., 2007) . ACS-1 treatment resulted in a dose-dependent decrease in c-myc protein that is not observed with okadaic acid, further verifying that PP2A is activated by ACS-1 and may contribute to the antiproliferative effects observed by ACS-1.
The PP2A holoenzyme is comprised of three subunits: a catalytic subunit (PP2A C ), a scaffolding subunit (PP2A A ) and a regulatory subunit (PP2A B ). Although PP2A is a ubiquitous protein and has phosphatase activity with a diverse array of substrates, the activity is tightly regulated. There are approximately 26 known regulatory subunits (PP2A B ) and the identity of the B subunit regulates multiple enzymatic parameters, such as substrate specificity, cellular localization and specific activity (Janssens and Goris, 2001; Eichhorn et al., 2009) . In addition to the array of B subunits that can potentially control phosphatase activity, there are also binding proteins, such as SET and a4, that can either inhibit or increase PP2A activity, respectively (Li et al., 1995; Prickett and Brautigan, 2006; Trotta et al., 2007) . In addition, altering the phosphorylation and methylation status of the PP2A subunits can further modulate PP2A activity (Chen et al., 1992; Longin et al., 2007; Xing et al., 2008) .
In addition to the multiple endogenous regulators of PP2A activity, pharmacological agents have been described that modulate PP2A activity. Forskolin induces PP2A activity by increasing intracellular cAMP levels (Feschenko et al., 2002) . However, ACS-1 did not cause an increase in cAMP, suggesting that cAMP is not a viable mechanism for ACS-1 activation of PP2A. FTY720, a synthetic analog of myriocin, has been shown to inhibit Akt activation by increasing PP2A activity in human leukemia cells (Matsuoka et al., 2003) . FTY720 also functions as a cannabinoid receptor type 1 (CB1) antagonist (Paugh et al., 2006) . Interestingly, another CB1 antagonist, SR141716, has antiproliferative effects in MB231 mouse xenografts and increases p27 KIP1 expression (Sarnataro et al., 2006) . These results are consistent with impaired Akt activity, as Akt signaling has proliferative effects and negatively regulates p27 KIP1 (Liang et al., 2002) . However, CB1 receptor antagonists can affect adenylate cyclase activity, and it is possible that FTY720 and other CB1 antagonists activate PP2A by an increase in cellular cAMP levels similar to forskolin. Endostatin, an antiangiogenic peptide, decreases ERK1/2 activity by increasing PP2A activity (Schmidt et al., 2006) . ACS-1 and similar compounds have also been shown to be antiangiogenic and we show here that these compounds activate PP2A (Isenberg et al., 2007) . The observed effects of endostatin on Akt/PP2A activity are similar to the effects observed with ACS-1 in this report, yet the mechanism of PP2A activation by endostatin is not known.
ACS-1 exerts antiproliferative effects independent of ARE activation as HO-1 protein expression did not change with respect to ACS-1 concentration. The effect of ACS-1 on Akt activation was not altered in the presence of a protein synthesis inhibitor, suggesting that the effects of ACS-1 are independent of de novo ARE ACS-1 increases PP2A activity CH Switzer et al gene products. Furthermore, phase II genes are not fully upregulated within the 2 h of ACS-1 treatment that results in PP2A activation, consistent with an alternate molecular target for dithiolethiones. S-NSAIDs that release ACS-1 have been shown to be antiangiogenic, which is contradictory to ARE activation, as HO-1 activity is associated with a proangiogenic response (Dulak et al., 2008) . In addition, HO-1 activates Akt in colon cancer cells and the Nrf2 activator carnosol upregulates HO-1 expression by ARE binding but also activates PI3K pathways, including Akt (Martin et al., 2004) (Busserolles et al., 2006) . Taken together, these observations suggest that ACS-1 activates PP2A, which mediates Akt inhibition in an Nrf2/ARE-independent manner, and identifies another chemical motif in addition to the KEAP1/Nrf2 complex targeted by dithiolethiones.
We also examined whether pAkt-(ser 473) suppression is mediated by other dithiolthione compounds. EGFstimulated MB231 cells exposed to ADT, Oltipraz and D3T showed similar inhibitory effects on Akt-(ser 473) phosphorylation (data not shown). Another unique aspect of this class of compounds is that they release H 2 S (Li et al., 2007) . However, H 2 S had no Akt inhibitory affects as shown by time course and doseresponse experiments carried out on MB231 cells 
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ACS-1 (µM) Figure 5 Okadaic acid (OA) abates the effect of ACS-1 on Akt activation. (a) Western blot and (b) densitometry analysis of Akt-(ser 473) phosphorylation in A549 cells incubated with ACS-1 and/or OA for 2 h and stimulated with epidermal growth factor (EGF) for 30 min. (c) ACS-1 increases PP2A activity as determined by total c-myc protein expression in MB231 cells treated with ACS-1 for 2 h. C-myc protein levels are not altered in the presence of OA. (d) Serum-starved MB231 cells were treated with ACS-1 for 2 h stimulated with EGF and lysed. PP2A (subunit C) was immunoprecipitated from whole cell extracts, washed with assay buffer and PP2A phosphatase activity measured. (e) ACS-1 does not affect the level of PP2A expression. Serum-starved MB231 cells were treated with ACS-1 for 2 h and stimulated with EGF for 30 min. PP2A and actin protein levels were determined by western blot analysis.
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The clinical applications of dithiolethione compounds may have unwanted Akt inhibition and associated pathologies such as diabetes; however, dithiolethione compounds release H 2 S on decomposition, which is known to activate Akt (Cai et al., 2007) . This feature of H 2 S release may alleviate systemic Akt inhibition by dithiolethiones. Furthermore, dithiolethiones prevent insulin resistance by inhibiting tumor necrosis factor-a induced S6 kinase-1 phsophorylation, consistent with mTOR inhibition presented here (Bae et al., 2007) . Therefore, the clinical use of dithiolethiones is not expected to develop pathological conditions of decreased Akt activity (that is, diabetes). A novel class of NSAIDs (S-NSAIDs) have recently been described, which incorporates the cytoprotective effects of dithiolethiones with the anti-inflammatory effects of COX inhibition by covalently linking an NSAID with ACS-1 (Li et al., 2007) . NSAIDs are useful cancer chemoprevention or chemotherapeutic agents due to the role of inflammation in the initiation, progression and metastasis of many human cancers; however, chronic NSAID administration is associated with gastrointestinal and cardiovascular toxicity (Guadagni et al., 2007) . S-NSAIDs dramatically reduce gut ulceration compared with the parent NSAID (Li et al., 2007) . In addition, S-NSAIDs exhibit antiangiogenic properties by increasing HSP-27 phosphorylation in endothelial cells (Isenberg et al., 2007) and potently inhibit some cytochrome P450 enzymes (Bass et al., 2009) . We have shown that S-NSAIDs have antiproliferative effects in lung cancer non-small cell lung carcinoma line both in vitro and in vivo (Moody et al., 2009) . Also, we have found that S-NSAIDs increase the radiation-induced tumor growth delay in a mouse xenograft model (unpublished results). Interestingly, S-NSAIDs, but not NSAIDs, cause an increase in E-cadherin expression in human cancer cells, suggesting a mesenchymal to epithelial transition in the phenotype of the transformed cell (Moody et al., 2009) . Taken together, these observations indicate that, although S-NSAIDs behave as NSAIDs with reduced toxicity, the Figure 6 ACS-1 effects PP2A activity independent of protein production or phase II activation. Serum-starved MB231 cells were treated with ACS-1 for 2 h. (a) Western blot analysis of HO-1 and actin indicate that ARE controlled genes are not upregulated within the time of PP2A activation by ACS-1. (b) MB231 cells were exposed to 50 mM ACS-1 for indicated times and the induction of phase II genes (UGTA1, GSTP1, GCT1 and GCLM) were measured by reverse transcription-PCR. (c) Effect of ACS-1 on cellular cAMP levels. MB231 cells were exposed to forskolin or ACS-1 for 2 h and cAMP was measured by enzyme-linked immunosorbent assay. Figure 7 Scheme of protein interactions. Akt is activated by convergent pathways in human cancers. ACS-1 inhibits Akt activation by increasing the activity of PP2A and not by altering epidermal growth factor receptor (EGFR) or integrin signaling.
ACS-1 increases PP2A activity CH Switzer et al dithiolethione moiety of S-NSAIDs has unique anticancer properties that are not attributable to either NSAID function or to ARE activation. The results of this report confirm that ACS-1 has antiproliferative effects on human cancer cell lines and establish the tumor suppressor PP2A as a novel effector molecule of dithiolethiones.
The above data demonstrate that dithiolethione compounds increase the activity of the tumor suppressor PP2A, and thus downregulates Akt and c-myc signaling. PP2A has recently emerged as a tumor suppressor, and pharmacological activation of PP2A appears to be a viable target in cancer chemotherapy (Perrotti and Neviani, 2008) . Few compounds have been shown to increase PP2A activity; however, we show here that dithiolethiones, usually associated with chemoprevention, can increase PP2A tumor suppressor activity. Moreover, ACS-1 is closely related to ADT, which is currently in clinical use. The findings reported here show another potential indication for this drug and suggest that other compounds with similar reactivity may have antiproliferative effects in human cancers.
Materials and methods
Cell culture and reagents A549 human lung carcinoma and MDA-MB-231 human breast adenocarcinoma cells (ATCC, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA, USA) containing 10% FBS (Atlanta Biologicals, Lawrenceville, GA, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (Sigma-Aldrich, St Louis, MO, USA) and passaged two to three times per week. ACS-1 was obtained from (Sulfidris, Milan, Italy). Human recombinant EGF, Akt and human FN were purchased from R&D Systems (Minneapolis, MN, USA). G418 was purchased from Invitrogen. Okadaic acid was purchased from Millipore (Billerica, MA, USA). P-Akt (serine 473), pan Akt, P-EGFR (tyrosine 992), EGFR, P-mTOR (serine 2448), antirabbit horseradish peroxidase antibodies were purchased from Cell Signaling (Danvers, MA, USA), and PP2A, actin and antimouse horseradish peroxidase were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Western blot analysis
Serum-starved cells were treated for 2 h with ACS-1 and stimulated with EGF for either 2 or 30 min at 37 1C. The cells were placed on ice and the media was aspirated and the cells were washed with cold phosphate-buffered saline (PBS). Cells were harvested in cold 2 Â RIPA lysis buffer supplemented with Protease Inhibitor Cocktail Set I (EMD Chemicals, Gibbstown, NJ, USA) and phenylmethylsulfonyl fluoride (Sigma-Aldrich), and stored at À80 1C. The whole cell lysates were cleared by centrifugation (14 000 Â g for 5 min at 4 1C) and the protein content was determined by BCA assay (Thermo Fisher Scientific, Rockford, IL, USA). Equal amounts of protein were loaded onto Novex 4-20% Tris-Glycine gradient gels (Invitrogen), separated by electrophoresis and were transferred to polyvinylidene difluoride membranes using the iBlot transfer system (Invitrogen). After blocking with 0.5% bovine serum albumin, the membranes were probed with rabbit polyclonal or mouse monoclonal antibodies and horseradish peroxidase-conjugated secondary antibodies using the SNAP i.d. protein detection system (Millipore). Membranes were imaged using the ECF Western blotting kit (GE Healthcare, Piscataway, NJ, USA) and recorded on a FluoroChem SP imaging system using AlphaEase FC software (Alpha Innotech, San Leandro, CA, USA). Images were further analysed using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA).
Proliferation assays
Cells (1 Â 10 5 ; A549 and MB231) were seeded in DMEM þ 10% FBS and incubated for 3 h to allow the cells adhere. The cells are washed (three times) with serum-free DMEM and incubated for the appropriate times with DMEM supplemented with 0.1% bovine serum albumin, EGF (100 ng/ ml) and the indicated concentration of ACS-1. After the indicated time of treatment, the media was removed, cells washed with PBS, trypsinized and counted with a Beckman Coulter Z2 particle counter and size analyzer (Beckman Coulter, Fullerton, CA, USA). Proliferation in the presence of 10% FBS was also assessed by the MTS assay using the CellTiter96 AQueous assay (Promega, Madison, WI, USA).
Cell cycle analysis MB231 cells were synchronized by overnight serum starvation and then incubated for 24 h in the presence of serum-free RPMI, RPMI þ 10% FBS or RPMI þ 10% FBS containing ACS-1. Cells were fixed in ethanol and treated with RNase A and Triton X-100 for 30 min at 37 1C. Cells were then stained with propidium iodide and analysed by flow cytometry.
FN activation
Petri dishes (60 mm) were coated with FN overnight at 4 1C, aspirated and blocked with PBS þ 1% bovine serum albumin for 30 min at room temperature. The coated plates were then washed with PBS and used immediately. Cultured A549 cells were trypsinized, washed in DMEM þ 10% FBS and then washed twice in serum-free DMEM. The cells were treated with ACS-1 for 30 min before plating on FN-coated plates. Cells were incubated on FN-coated plates for 2 h, placed on ice, washed with cold PBS and lysed as described for western blot analysis.
ILK kinase assay
Integrin-linked kinase kinase assay was carried out as previously described with modification (Sawai et al., 2006) . A549 cells were incubated with ACS-1 for 30 min at 37 1C and plated on FN-coated (5 mg/cm 2 ) dishes for 2 h. Cells were lysed with lysis buffer and cleared lysate was immunoprecipitated overnight with anti-ILK antibody at 4 1C. Antibody complexes were isolated with Protein A/G PLUS-Agarose beads (Santa Cruz Biotechnology) for 3 h at 4 1C and washed three times in lysis buffer. ILK activity was assayed by incubating the immunoprecipitated protein with glutathione S-transferase-Akt (2 mg; recombinant human, R&D Systems) in kinase reaction buffer (50 mM HEPES, pH 7.0, 200 mM ATP, 2 mM MgCl 2 , 2 mM MnCl 2 , 200 mM NaVO 4 , 200 mM NaF) for 30 min at 37 1C. Proteins were heat denatured in 4 Â SDS-loading buffer at 90 1C for 5 min. ILK and Phospho-Akt (ser 473) were detected by western blot analysis.
Phosphatase activity assay
Cells (A549 or MB231) were treated with the same ACS-1/ EGF regime as above and whole cell lysates were collected. PP2A was immunoprecipitated by incubating the cleared lysate with anti-PP2A subunit C overnight at 4 1C and then conjugated with Protein A/G PLUS-Agarose beads for 3 h at 4 1C. The beads were washed three times in PP2A assay buffer (100 mM Tris-HCl, pH 8.0, 2 mM DTT, 1 mM MnCl 2 and 0.01% Brij 35) and then incubated for 30 min at 30 1C in 100 ml of the same buffer containing 2 mM of the PP2A phosphopeptide substrate Arg-Arg-Ala-pThr-Val-Ala (BIOMOL International, Plymouth Meeting, PA, USA). The reaction was terminated by placing the samples on ice, and the amount of phosphate released from the peptide substrate was determined using the Malachite green assay (Echelon Bioscience, Salt Lake City, UT, USA).
Statistical analysis
Data represented are mean of at least three independent experiments±s.d. Statistical comparisons were carried out by one-way analysis of variance with Dunnett post-test analysis and significance was indicated by Po0.05.
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